SCHEMBL973396

SCHEMBL973396

Cc1cccc(C#CC(=O)N(C)CCN(C)c2nccs2)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.39
ALOX5 P09917 1/20 0.38
FFAR1 O14842 3/20 0.37
TRPM8 Q7Z2W7 1/20 0.35
CTSA P10619 1/20 0.35
LMNA P02545 2/20 0.34
EGLN1 Q9GZT9 1/20 0.34
PPARG P37231 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
VCP P55072 1/20 0.34
GAA P10253 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
RAB9A P51151 1/20 0.33
TSHR P16473 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL972388 0.88 GRM5 (0.40) GRM5FFAR1CTSATSHR
SCHEMBL971987 0.88 GRM5 (0.41) GRM5CTSALMNAPPARGNPSR1
SCHEMBL971740 0.88 NPSR1 (0.47) GRM5FFAR1TRPM8LMNAPPARG
SCHEMBL973633 0.83 VCP (0.38) GRM5ALOX5FFAR1TRPM8CTSA
SCHEMBL14024208 0.81 NPSR1 (0.45) GRM5FFAR1TRPM8LMNAPPARG
SCHEMBL971722 0.79 GRM5 (0.40) GRM5FFAR1PPARGNPSR1
SCHEMBL974786 0.74 PPARG (0.37) FFAR1TRPM8LMNAPPARGGAA
SCHEMBL4186373 0.72 FFAR1 (0.52) FFAR1NPSR1NPC1RAB9AFFAR4
SCHEMBL973186 0.72 PYGL (0.41) GRM5CTSALMNAVCPGAA
SCHEMBL972786 0.72 NPSR1 (0.47) GRM5FFAR1TRPM8LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871999-B2 Substituted thiazoles and their use for producing drugs GRUENENTHAL GMBH (DE) 2011-01-18 US claimed
EP-1968957-B1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2010-01-20 EP claimed
US-20090176756-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-07-09 US claimed
US-7871999-B2 Substituted thiazoles and their use for producing drugs GRUENENTHAL GMBH (DE) 2011-01-18 US disclosed
EP-1968957-B1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2010-01-20 EP disclosed
US-20090176756-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-07-09 US disclosed
WO-2007079960-A9 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2008-10-23 WO disclosed
EP-1968957-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP disclosed
WO-2007079960-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176756-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS TPMT, SLC5A2, DPP4 GRM5 1623/4885ALOX5 1650/4885FFAR1 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.